A Open-Label Study Of CP-690,550 As Long-Term Therapy (48 Weeks) In Subjects With Crohn's Disease
NCT01470599
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
150
Enrollment
INDUSTRY
Sponsor class
Conditions
Crohn's Disease
Interventions
DRUG:
CP-690,550
DRUG:
CP-690,550
Sponsor
Pfizer